ライフサイエンスコーパス: ehrlichiosis

1 osis (previously known as human granulocytic ehrlichiosis).

2 an anaplasmosis (formerly human granulocytic ehrlichiosis).

3 ne bacterium responsible for human monocytic ehrlichiosis.

4 rlichia canis, the etiologic agent of canine ehrlichiosis.

5 tic bacterium that causes human granulocytic ehrlichiosis.

6 cytophila an etiologic agent of granulocytic ehrlichiosis.

7 m of granulocytes, causes human granulocytic ehrlichiosis.

8 en for the serodiagnosis of canine monocytic ehrlichiosis.

9 vaccine candidate immunogenic against canine ehrlichiosis.

10 ion of cytokines and chemokines during fatal ehrlichiosis.

11 se of murine Lyme arthritis and granulocytic ehrlichiosis.

12 ion in the serodiagnosis of canine monocytic ehrlichiosis.

13 agocytophila, an agent of human granulocytic ehrlichiosis.

14 tes and macrophages, causes canine monocytic ehrlichiosis.

15 ng human diseases monocytic and granulocytic ehrlichiosis.

16 llular bacterium that causes human monocytic ehrlichiosis.

17 ul for serodiagnosis of human monocytotropic ehrlichiosis.

18 tial antigen for the serodiagnosis of canine ehrlichiosis.

19 ransmits Lyme disease and human granulocytic ehrlichiosis.

20 with convalescent sera from dogs with canine ehrlichiosis.

21 gen for the serodiagnosis of human monocytic ehrlichiosis.

22 tion in the serodiagnosis of human monocytic ehrlichiosis.

23 y and toxic shock in a murine model of fatal ehrlichiosis.

24 and rapid serodiagnosis for human monocytic ehrlichiosis.

25 ntibodies to the agent of human granulocytic ehrlichiosis.

26 affeensis or the agent of human granulocytic ehrlichiosis.

27 . canis, and the agent of human granulocytic ehrlichiosis.

28 affeensis or the agent of human granulocytic ehrlichiosis.

29 sulting in disease manifestations that mimic ehrlichiosis.

30 tection is not afforded against granulocytic ehrlichiosis.

31 entations compatible with human granulocytic ehrlichiosis.

32 tsu is the causative agent of human Sennetsu ehrlichiosis.

33 s, is the etiologic agent of human monocytic ehrlichiosis.

34 nsistent, and rapid serodiagnosis for canine ehrlichiosis.

35 substrate for identifying human granulocytic ehrlichiosis.

36 ly for the diagnosis of human monocytotropic ehrlichiosis.

37 ted from a patient from Oklahoma with severe ehrlichiosis.

38 sible for both equine and human granulocytic ehrlichiosis.

39 llular bacterium that causes human monocytic ehrlichiosis.

40 dual with prior confirmed human granulocytic ehrlichiosis.

41 NA in blood samples from human patients with ehrlichiosis.

42 ed with babesiosis was also seropositive for ehrlichiosis.

43 biting clinical signs compatible with canine ehrlichiosis.

44 t variables in experimentally induced canine ehrlichiosis.

45 diagnose and ascertain the cause of cases of ehrlichiosis.

46 nd is the etiologic agent of human monocytic ehrlichiosis.

47 c ehrlichia, the agent of human granulocytic ehrlichiosis.

48 on, which contribute to development of fatal ehrlichiosis.

49 llular bacterium that causes human monocytic ehrlichiosis.

50 s clinical outcome for patients suspected of ehrlichiosis.

51 another laboratory tool for the diagnosis of ehrlichiosis.

52 l, is the causative agent of human monocytic ehrlichiosis.

53 ick-borne causative agent of human monocytic ehrlichiosis.

54 the most recently recognized agent of human ehrlichiosis.

55 d with tick-transmitted human monocytotropic ehrlichiosis.

56 ent of globally distributed canine monocytic ehrlichiosis.

57 s during the acute phase of canine monocytic ehrlichiosis.

58 organism, causes the disease human monocytic ehrlichiosis.

59 hrlichia muris mouse model of monocytotropic ehrlichiosis.

60 ent, causes human monocyte/macrophage-tropic ehrlichiosis.

61 mbles the fatal form of human monocytotropic ehrlichiosis.

62 evelopment of a vector transmission model of ehrlichiosis.

63 a phagocytophilum, the agent of granulocytic ehrlichiosis.

64 philum causes the disease human granulocytic ehrlichiosis.

65 gated the signals that activate HSPCs during ehrlichiosis, a disease characterized by profound hemato

66 Human ehrlichiosis, a newly described zoonotic infection, can

67 ed strain of the agent of human granulocytic ehrlichiosis, a recently described emerging rickettsial

68 n monocytic ehrlichiosis; human granulocytic ehrlichiosis; a novel cat flea-associated typhus group r

69 Ehrlichiosis acquired from transfusion of blood products

70 The human granulocytic ehrlichiosis agent (HGEa) survives extreme differences b

71 repeat units of the human granulocytotropic ehrlichiosis agent 130-kDa protein and of the fimbria-as

72 ribes the kinetics of the human granulocytic ehrlichiosis agent in the blood of horses experimentally

73 ia equi in horses and two human granulocytic ehrlichiosis agent isolates in California for sequence d

74 of Ehrlichia equi or the human granulocytic ehrlichiosis agent to assess the suitability of differen

75 Anaplasma phagocytophila (human granulocytic ehrlichiosis agent) are encoded by the p44 multigene fam

76 The human granulocytic ehrlichiosis agent, Anaplasma phagocytophila, resides an

77 The equine granulocytic ehrlichiosis agent, Ehrlichia equi, is closely related o

78 from E. chaffeensis, the human granulocytic ehrlichiosis agent, or Ehrlichia muris DNA.

79 a phagocytophila, and the human granulocytic ehrlichiosis agent.

80 haffeensis but not in the human granulocytic ehrlichiosis agent.

81 le antibodies against the human granulocytic ehrlichiosis agent; however, only 2 had a 4-fold antibod

82 n together, these results suggest that human ehrlichiosis agents became cholesterol dependent due to

83 To understand whether human monocytotropic ehrlichiosis also occurs in this northeastern geographic

84 aackii), increases human risk of exposure to ehrlichiosis, an emerging infectious disease caused by b

85 anemia in a murine model of human monocytic ehrlichiosis, an emerging tick-borne disease.

86 s and the etiologic agent of human monocytic ehrlichiosis, an emerging zoonosis.

87 Human monocytic ehrlichiosis, an influenza-like illness accompanied by s

88 The agent of human granulocytic ehrlichiosis (Anaplasma phagocytophilum) is intensely en

89 we tested 78 dogs suspected of having acute ehrlichiosis and 10 healthy dogs.

90 dren with clinical signs suggestive of human ehrlichiosis and 43 apparently healthy adults who had a

91 nostic and vaccine antigens for granulocytic ehrlichiosis and aid in the classification of genogroup

92 a useful method for early detection of human ehrlichiosis and determination of etiology when serologi

93 in sera both from patients with granulocytic ehrlichiosis and from patients with monocytotropic ehrli

94 an important role in the pathophysiology of ehrlichiosis and immune responses to it.

95 rate for the detection of human granulocytic ehrlichiosis and should be used solely for the diagnosis

96 ma phagocytophilum causes human granulocytic ehrlichiosis and specifically infects and multiplies in

97 an anaplasmosis (formerly human granulocytic ehrlichiosis) and human monocytic ehrlichiosis (HME) are

98 d samples from seven patients with monocytic ehrlichiosis, and Amblyomma americanum ticks collected i

99 tickborne infectious diseases (Lyme disease, ehrlichiosis, and babesiosis) was conducted among 230 re

100 p44 gene of the agent of human granulocytic ehrlichiosis (aoHGE) encodes a 44-kDa major outer surfac

101 nsmission of the agent of human granulocytic ehrlichiosis (aoHGE) to guinea pigs.

102 kinetics of the agent of human granulocytic ehrlichiosis (aoHGE) were examined after needle and tick

103 rodents with the agent of human granulocytic ehrlichiosis (aoHGE).

104 Anaplasmosis and ehrlichiosis are emerging tick-borne diseases with clini

105 naling promotes host susceptibility to fatal ehrlichiosis, because it mediates ehrlichia-induced immu

106 ither dog had clinical signs attributable to ehrlichiosis, both dogs were anemic and neutropenic and

107 nsis, the causative agent of human monocytic ehrlichiosis, but natural infection in deer has not been

108 d leukocytes from 413 patients with possible ehrlichiosis by broad-range and species-specific polymer

109 assays for the diagnosis of canine monocytic ehrlichiosis by comparing them to the indirect fluoresce

110 gents of Lyme disease and human granulocytic ehrlichiosis by individual ticks was equally efficient a

111 nsis, the etiologic agent of human monocytic ehrlichiosis, can cause hepatitis of various levels of s

112 ly with serum antibodies from suspect canine ehrlichiosis cases that were positive for E. canis by im

113 udy, we used a model of fatal monocytotropic ehrlichiosis caused by Ehrlichia bacteria from Ixodes ov

114 Human monocytotropic ehrlichiosis caused by Ehrlichia chaffeensis is a life-t

115 Human monocytotropic ehrlichiosis caused by Ehrlichia chaffeensis was reporte

116 y to Ehrlichia and the pathogenesis of fatal ehrlichiosis caused by infection with low- and high-dose

117 in severe disease in a mouse model of fatal ehrlichiosis caused by Ixodes ovatus Ehrlichia (IOE).

118 lized a murine model of fatal monocytotropic ehrlichiosis caused by Ixodes ovatus ehrlichia.

119 ues by using murine models of mild and fatal ehrlichiosis caused by related monocytotropic Ehrlichia

120 Our data suggest that fatal ehrlichiosis could be a multistep process, where TNF-alp

121 s with confirmed or probable human monocytic ehrlichiosis due to E. chaffeensis also had antibodies t

122 Immune responses against monocytotropic ehrlichiosis during infection with a strain of Ehrlichia

123 Borrelia burgdorferi) and human granulocytic ehrlichiosis (Ehrlichia phagocytophila) are both transmi

124 a, including the agent of human granulocytic ehrlichiosis, Ehrlichia phagocytophila, and the bovine p

125 llular bacterium that causes human monocytic ehrlichiosis, encodes a single protein that contains a G

126 ed to correctly diagnose most cases of human ehrlichiosis, especially in geographic regions where bot

127 osely resemble those of human monocytotropic ehrlichiosis for which it is a promising model for inves

128 om patients who were clinically suspected of ehrlichiosis from 1 May to 1 August 2008 at Vanderbilt U

129 hiosis and from patients with monocytotropic ehrlichiosis from New York State.

130 rlichia canis, the causative agent of canine ehrlichiosis, from a human in Venezuela.

131 Six granulocytic ehrlichiosis (GE) types were identified.

132 1(-/-) mice were highly susceptible to fatal ehrlichiosis, had overwhelming infection, and developed

133 gdorferi and the agent of human granulocytic ehrlichiosis have been documented.

134 n isolate of the agent of human granulocytic ehrlichiosis (HGE agent) from infected mice to larval ti

135 lot analyses containing a human granulocytic ehrlichiosis (HGE) agent (NCH-1 strain) were used to con

136 f A. phagocytophilum, the human granulocytic ehrlichiosis (HGE) agent and a variant (AP-Variant 1) th

137 a cultured isolate of the human granulocytic ehrlichiosis (HGE) agent by using an indirect immunofluo

138 ure isolate (USG3) of the human granulocytic ehrlichiosis (HGE) agent has identified a number of immu

139 passage of in vitro-grown human granulocytic ehrlichiosis (HGE) agent in horses.

140 The human granulocytic ehrlichiosis (HGE) agent in infected blood specimens rem

141 r membrane protein of the human granulocytic ehrlichiosis (HGE) agent is an immunodominant antigen in

142 and macrophages, and the human granulocytic ehrlichiosis (HGE) agent is an obligatory intracellular

143 rin (n = 1) counties, and human granulocytic ehrlichiosis (HGE) agent isolates were obtained from Hum

144 The human granulocytic ehrlichiosis (HGE) agent resides and multiplies exclusiv

145 rRNA gene, the DNA of the human granulocytic ehrlichiosis (HGE) agent was detected in 17 of 47 mice (

146 A human granulocytic ehrlichiosis (HGE) agent with 16S rDNA sequence identica

147 The human granulocytic ehrlichiosis (HGE) agent, which replicates in neutrophil

148 ne proteins (OMPs) of the human granulocytic ehrlichiosis (HGE) agent, with molecular sizes of 44 to

149 ntibodies reactive to the human granulocytic ehrlichiosis (HGE) agent.

150 lated or identical to the human granulocytic ehrlichiosis (HGE) agent.

151 tophila, and the agent of human granulocytic ehrlichiosis (HGE) amplified DNA from extracts of these

152 od for early detection of human granulocytic ehrlichiosis (HGE) and determination of etiology when se

153 blood from patients with human granulocytic ehrlichiosis (HGE) and from infected HL60 cell cultures.

154 response in patients with human granulocytic ehrlichiosis (HGE) and in mice infected with the HGE age

155 Human granulocytic ehrlichiosis (HGE) and Lyme borreliosis (LB) are acquire

156 servoirs for the agent of human granulocytic ehrlichiosis (HGE) are suspected to be the small mammals

157 Lyme disease and human granulocytic ehrlichiosis (HGE) are tick-borne illnesses caused by Bo

158 were suspected of having human granulocytic ehrlichiosis (HGE) but who lacked antibodies to ehrlichi

159 ank gene of the agent of human granulocytic ehrlichiosis (HGE) codes for a protein with a predicted

160 the sera of patients with human granulocytic ehrlichiosis (HGE) commonly recognize a 44-kDa antigen.

161 lated from a patient with human granulocytic ehrlichiosis (HGE) developed anemia and leukopenia, but

162 The incidence of human granulocytic ehrlichiosis (HGE) in the upper Midwest is uncertain.

163 Human granulocytic ehrlichiosis (HGE) is a febrile tick-borne illness cause

164 Human granulocytic ehrlichiosis (HGE) is a newly described illness with few

165 The agent of human granulocytic ehrlichiosis (HGE) is a newly recognized tick-borne path

166 Human granulocytic ehrlichiosis (HGE) is a potentially fatal, tick-borne di

167 Human granulocytic ehrlichiosis (HGE) is a tickborne illness caused by an a

168 Human granulocytic ehrlichiosis (HGE) is an emerging febrile systemic disea

169 Human granulocytic ehrlichiosis (HGE) is an emerging infection caused by an

170 Human granulocytic ehrlichiosis (HGE) is an emerging tick-borne infection w

171 The agent of human granulocytic ehrlichiosis (HGE) is an emerging tick-borne pathogen th

172 Human granulocytic ehrlichiosis (HGE) is an emerging tick-borne zoonosis ca

173 Human granulocytic ehrlichiosis (HGE) is an emerging tickborne illness caus

174 Human granulocytic ehrlichiosis (HGE) is an emerging tickborne infection re

175 Human granulocytic ehrlichiosis (HGE) is an emerging tickborne infection, i

176 The agent of human granulocytic ehrlichiosis (HGE) is an obligate intracellular bacteriu

177 The etiologic agent of human granulocytic ehrlichiosis (HGE) is an obligate intracellular bacteriu

178 Human granulocytic ehrlichiosis (HGE) is caused by an agent that is nearly

179 Human granulocytic ehrlichiosis (HGE) is caused by infection with an obliga

180 Human granulocytic ehrlichiosis (HGE) is usually diagnosed by immunofluores

181 tic ehrlichiosis (HME) or human granulocytic ehrlichiosis (HGE) may be made on the basis of serologic

182 Human granulocytic ehrlichiosis (HGE) results in fever, pancytopenia, and m

183 Previous studies of human granulocytic ehrlichiosis (HGE) suggest a role for host immune respon

184 nfected with the agent of human granulocytic ehrlichiosis (HGE) to evaluate the importance of these p

185 response to the agent of human granulocytic ehrlichiosis (HGE) was assessed in a murine infection mo

186 nsmission of the agent of human granulocytic ehrlichiosis (HGE) was determined by removing feeding ti

187 ntibodies to the agent of human granulocytic ehrlichiosis (HGE) was developed and standardized.

188 s containing the agent of Human Granulocytic Ehrlichiosis (HGE) was studied to investigate how this p

189 m patients with confirmed human granulocytic ehrlichiosis (HGE) were tested for cytoplasmic, nuclear,

190 p44 genes of the agent of human granulocytic ehrlichiosis (HGE) with primers flanking the hypervariab

191 a murine model system of human granulocytic ehrlichiosis (HGE), C3H/HeJ, C3H-SCID, and Peromyscus le

192 gocytophila, the agent of human granulocytic ehrlichiosis (HGE), Ehrlichia canis, Bartonella henselae

193 The agent of human granulocytic ehrlichiosis (HGE), Ehrlichia phagocytophila, and Ehrlic

194 The agent of human granulocytic ehrlichiosis (HGE), Ehrlichia phagocytophila, and Ehrlic

195 gocytophila, the agent of human granulocytic ehrlichiosis (HGE), in different groups of adults and ch

196 fection with the agent of human granulocytic ehrlichiosis (HGE), regardless of host species.

197 In patients with human granulocytic ehrlichiosis (HGE), the HGE agent has been seen only in

198 th the etiologic agent of human granulocytic ehrlichiosis (HGE).

199 ts with culture-confirmed human granulocytic ehrlichiosis (HGE).

200 ffeensis and the agent of human granulocytic ehrlichiosis (HGE).

201 life-threatening illness, human granulocytic ehrlichiosis (HGE).

202 n particular the agent of human granulocytic ehrlichiosis (HGE).

203 omologues in the agent of human granulocytic ehrlichiosis (HGE).

204 tic ehrlichiosis (HME) or human granulocytic ehrlichiosis (HGE).

205 anulocytic ehrlichiosis) and human monocytic ehrlichiosis (HME) are emerging tick-borne infections ca

206 nine culture-proven cases of human monocytic ehrlichiosis (HME) caused by Ehrlichia chaffeensis.

207 s, rheumatoid arthritis, and human monocytic ehrlichiosis (HME) did not react with HGE-44-MBP antigen

208 Diagnosis of human monocytotropic ehrlichiosis (HME) generally depends on serology that de

209 We report the second case of human monocytic ehrlichiosis (HME) in a liver transplant recipient, and

210 Human monocytic ehrlichiosis (HME) is a tick-borne disease caused by Ehr

211 Human monocytotropic ehrlichiosis (HME) is an emerging, life-threatening, inf

212 Human monocytic ehrlichiosis (HME) is caused by a tick-borne obligate in

213 that incorrect diagnoses of human monocytic ehrlichiosis (HME) or human granulocytic ehrlichiosis (H

214 ection, can be classified as human monocytic ehrlichiosis (HME) or human granulocytic ehrlichiosis (H

215 and causes potentially fatal human monocytic ehrlichiosis (HME) that mimics toxic-shock-like syndrome

216 Human monocytotropic ehrlichiosis (HME), an emerging and often life-threateni

217 ia chaffeensis, the agent of human monocytic ehrlichiosis (HME), Babesia microti, and Borrelia burgdo

218 nsis, the etiologic agent of human monocytic ehrlichiosis (HME), has been extensively studied as a ca

219 eptibility and resistance to human monocytic ehrlichiosis (HME), immunocompetent and immunocompromise

220 al agent, is responsible for human monocytic ehrlichiosis (HME).

221 llular bacterium that causes human monocytic ehrlichiosis (HME).

222 nd is the etiologic agent of human monocytic ehrlichiosis (HME).

223 eatment with doxycycline for human monocytic ehrlichiosis (HME).

224 ythema migrans-like illness; human monocytic ehrlichiosis; human granulocytic ehrlichiosis; a novel c

225 e found at sites where cases of granulocytic ehrlichiosis in a horse and a llama had recently occurre

226 ltivation of the agent of human granulocytic ehrlichiosis in cell culture.

227 5 patients diagnosed with human granulocytic ehrlichiosis in Connecticut were tested by indirect IFA

228 eviously reported as a cause of granulocytic ehrlichiosis in dogs.

229 is and E. ewingii have been thought to cause ehrlichiosis in humans in the United States.

230 gents of Lyme disease and human granulocytic ehrlichiosis in I. scapularis ticks.

231 An animal model to study acute fatal ehrlichiosis in mice that has been developed closely res

232 identical to the agent of human granulocytic ehrlichiosis in Minnesota and Wisconsin and to be very s

233 lecular evidence indicates that granulocytic ehrlichiosis in Minnesota and Wisconsin dogs is not caus

234 On testing, four cases of ehrlichiosis in Minnesota or Wisconsin were found not to

235 irst recognized cases of equine granulocytic ehrlichiosis in New England are described.

236 first recognized case of human granulocytic ehrlichiosis in Rhode Island.

237 is the predominant etiologic agent of canine ehrlichiosis in the areas of Missouri included in this s

238 Department of Health for human granulocytic ehrlichiosis in the residents of Westchester County, N.Y

239 rophages and is the etiologic agent of human ehrlichiosis in the United States.

240 ry findings suggestive of human granulocytic ehrlichiosis, including unexplained fever after probable

241 ies in a mouse model of human monocytotropic ehrlichiosis indicated that CD8 T cells are not essentia

242 nd is the causative agent of human monocytic ehrlichiosis infections.

243 The agent of human granulocytic ehrlichiosis infects mostly neutrophils, it transmitted

244 Thus, during monocytotropic ehrlichiosis, inflammatory cytokine production, by CD8 T

245 Ehrlichiosis is a clinically important, emerging zoonosi

246 Human granulocytic ehrlichiosis is a potentially fatal tick-borne infection

247 Human ehrlichiosis is a recently recognized tick-borne infecti

248 Ehrlichiosis is a tick-borne disease that ranges in seve

249 Human monocytic ehrlichiosis is an emerging infectious disease caused by

250 Human granulocytic ehrlichiosis is an emerging infectious disease in the Un

251 Human monocytic ehrlichiosis is an emerging tick-borne disease caused by

252 Human monocytic ehrlichiosis is an emerging tick-borne disease caused by

253 We have shown that fatal murine ehrlichiosis is associated with CD8(+)T cell-mediated ti

254 Human monocytic ehrlichiosis is caused by a tick-transmitted rickettsia,

255 Ehrlichia chaffeensis and human granulocytic ehrlichiosis is caused by an agent similar to Ehrlichia

256 Human monocytic ehrlichiosis is caused by Ehrlichia chaffeensis and huma

257 Human monocytotropic ehrlichiosis is caused by Ehrlichia chaffeensis, a Gram-

258 he molecular diagnosis of human granulocytic ehrlichiosis is discussed.

259 Human monocytic ehrlichiosis is one of the most prevalent tick-borne zoo

260 a, the etiologic agent of human granulocytic ehrlichiosis, is an emerging bacterial pathogen that inv

261 tein of Ehrlichia canis, the agent of canine ehrlichiosis, is the major antigen recognized by both na

262 nsis, the causative agent of human monocytic ehrlichiosis, is transmitted by Amblyomma americanum tic

263 are intracellular bacteria that cause fatal ehrlichiosis, mimicking toxic shock syndrome in humans a

264 p., p44 from the agent of human granulocytic ehrlichiosis, msp-2 and msp-4 from Anaplasma marginale,

265 rophils, was positive for human granulocytic ehrlichiosis on PCR.

266 Human monocytic ehrlichiosis, one of the most frequent life-threatening

267 Serum from human ehrlichiosis patients also contained polyreactive and se

268 ve in peripheral blood leukocytes from human ehrlichiosis patients and experimentally infected animal

269 eensis-infected dog and human monocytotropic ehrlichiosis patients.

270 ae, the causative agents of anaplasmosis and ehrlichiosis, persist in the bloodstream of their mammal

271 newly identified tick-borne diseases such as ehrlichiosis raise additional questions about the role o

272 Antibodies from patients and dogs with ehrlichiosis reacted strongly with recombinant TR region

273 rent antibody testing for human granulocytic ehrlichiosis relies predominantly on indirect fluorescen

274 st, the risk of acquiring human granulocytic ehrlichiosis remains minimal despite the abundance of ap

275 nsis, the etiologic agent of human monocytic ehrlichiosis, replicates in early endosomes by avoiding

276 e bovine anaplasmosis and human granulocytic ehrlichiosis, respectively.

277 m, the causative agent of human granulocytic ehrlichiosis, results in downregulation of the gp91(phox

278 Patients with suspected ehrlichiosis routinely undergo testing to ensure proper

279 Human ehrlichiosis should be included in the differential diag

280 d ticks with the agent of human granulocytic ehrlichiosis, suggesting that these rodents serve as res

281 e, are much less susceptible to granulocytic ehrlichiosis than are control animals.

282 ve used a newly described model of monocytic ehrlichiosis that results from infection of mice by an e

283 suitable antigen for serodiagnosis of canine ehrlichiosis, the immunoreactions between rP30 and the w

284 ma phagocytophilum causes human granulocytic ehrlichiosis, the second most common tick-borne disease

285 m patients with confirmed human granulocytic ehrlichiosis (three from New York, four from Wisconsin,

286 tand these changes, we used a mouse model of ehrlichiosis to determine whether the observed hematolog

287 -borne illness was suspected and testing for ehrlichiosis was negative.

288 The causative agent of human granulocytic ehrlichiosis was recently reclassified as Anaplasma phag

289 gocytophila (the agent of human granulocytic ehrlichiosis), was evaluated by class-specific enzyme-li

290 . canis, a widely recognized agent of canine ehrlichiosis, was not detected in any animal.

291 s of susceptibility to severe monocytotropic ehrlichiosis, we compared low and high doses of the high

292 Using a murine model of fatal ehrlichiosis, we investigated the role of CD1d-restricte

293 In a mouse model of ehrlichiosis, we observed that infection-induced prolife

294 rom dogs with clinical signs compatible with ehrlichiosis were examined for infection of Ehrlichia ca

295 tologic abnormalities associated with canine ehrlichiosis were tested by IFA assay and by recombinant

296 r complete protection against monocytotropic ehrlichiosis, which is associated with a strong cell-med

297 igated as a more appropriate model of canine ehrlichiosis, which is naturally transmitted by arthropo

298 A case of fatal ehrlichiosis with rapidly progressive myocarditis and mu

299 this study was to develop a mouse model for ehrlichiosis with the newly discovered human pathogen, E

300 d limb edema, typical of granulocytic equine ehrlichiosis, within 1 week.